Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): Preliminary results from a larger registry in the U.S

Mark Kozloff,Allen Lee Cohn,N Christiansen,Patrick J. Flynn,Fairooz F. Kabbinavar,R. Robles,M. Ulcickas Yood,Somnath Sarkar,Julie Hambleton,A. Grothey

Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): Preliminary results from a larger registry in the U.S

2005

Mark Kozloff
Allen Lee Cohn
N Christiansen
Patrick J. Flynn
Fairooz F. Kabbinavar
R. Robles
M. Ulcickas Yood
Somnath Sarkar
Julie Hambleton
A. Grothey

3566 Background: In a phase III pivotal trial in pts with mCRC, BV (Avastin) increased overall survival when added to first-line irinotecan, fluorouracil, and leucovorin. Safety data from that tria...

Keywords:

Physical therapy
Bevacizumab
Cancer research
Colorectal cancer
Oncology
Internal medicine
Chemotherapy
Medicine
Fluorouracil
Irinotecan
first line chemotherapy
overall survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations